February 2022 FDA Recall Paliperidone by The Harvard Drug Group
D-0649-2022 - Failed Dissolution Specifications

This Class II drug recall was voluntarily initiated by The Harvard Drug Group on February 28, 2022 for the product Paliperidone. The FDA reported the reason for recall as failed dissolution specifications. The product was distributed Nationwide and the recall is currently terminated.

Recall Number: D-0649-2022

Reason for Recall
Failed Dissolution Specifications
Initiated
02-28-2022
Reported
03-16-2022
Quantity
174 cartons

Recall Profile & Regulatory Data

Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
The Harvard Drug Group
Nationwide within the United States
PALIPERIDONE EXTENDED-RELEASE TABLETS, 9 mg, 100 Tablets per carton (10 x 10 blister packs), Rx only, Manufactured by: Sun Pharmaceutical Industries Ltd., Survey No. 259/15, Dadra-396 191, India. Distributed by: MAJOR PHARMACEUTICALS, 17177 N. Laurel Park Dr., Suite 233, Livonia, MI 48152. NDC: 0904-6937-61

Batch or Lot Expiration Information

Lot# : N00522, Exp. Date 09/2022; N00618, Exp. Date 11/2022